A Study of Acalabrutinib in Combination with Rituximab + (Bendamustine or Venetoclax) in Subjects with MCL

Study identifier:ACE-LY-106

ClinicalTrials.gov identifier:NCT02717624

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

Medical condition

Mantle Cell Lymphoma (MCL)

Phase

Phase 1

Healthy volunteers

No

Study drug

Acalabrutinib in combination with BR, Acalabrutinib in combination with VR

Sex

All

Actual Enrollment

72

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 20 Apr 2016
Primary Completion Date: 15 Jun 2022
Estimated Study Completion Date: 20 Aug 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

AstraZeneca

Inclusion and exclusion criteria